Phase 1 Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For Part 1:
- People who have been diagnosed with a confirmed advanced-stage (Stage III or IV) high-grade cancer of the ovaries, fallopian tubes, or peritoneum of a specific type (serous or endometrioid).
- People who have received 1 or 2 previous treatment courses for advanced or spread cancer, where at least one treatment included a platinum-based chemotherapy drug (cisplatin or carboplatin).
- People whose cancer came back within 6 months of their last platinum-based treatment, or whose cancer did not respond to that treatment at all.
For Part 2 – Dose Escalation:
- People who have completed 6 cycles of platinum-based combination chemotherapy as their most recent treatment (either first or second course of treatment).
- People whose cancer showed a complete response, partial response, or stable disease during their first course of platinum-based chemotherapy.
- People in their second course of treatment whose cancer progressed more than 183 days after their last platinum dose in the first course, and whose cancer then showed a complete response, partial response, or stable disease to the second course of platinum chemotherapy.
- People with adequate blood counts and organ function.
For Part 2 – Dose Expansion:
- People who have completed at least 4 cycles of platinum-based chemotherapy as a second course of treatment and whose cancer showed a complete response, partial response, or stable disease.
- People whose cancer progressed while receiving a specific type of maintenance therapy drug called a PARP inhibitor after their first course of treatment.
Who may not be able to join:
- People whose cancer has been diagnosed as an abdominal cancer of unknown origin, or as a borderline ovarian tumour.
- People with a cancer type called carcinosarcoma, even if it contains a serous component.
- People with a serious illness or significant medical condition (confirm with trial site for specifics).
- People who have a second cancer that is active, uncontrolled, has spread, or currently requires treatment.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 8582634333
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Part 1: To investigate the safety and tolerability of azenosertib in combination with PLD, carboplatin, paclitaxel, or gemcitabine; Part 1: To identify the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) of azenosertib in combination with PLD, carboplatin, paclitaxel, or gemcitabine; Part 2: To estimate the safety/tolerability of azenosertib in combination with bevacizumab; Part 2: To identify the recommended dose for Part 2 Dose Expansion
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.